BioCryst Says Orladeyo On Slow, Steady Ramp To Blockbuster Sales
Company believes its oral HAE prophylaxis will gradually reach the billion-dollar sales threshold, with about 80% of revenue coming from the US market.
You may also be interested in...
CSL Seeks Disruption Of HAE Space With Monthly Prevention Product
Based on top-line Phase III data for garadacimab, CSL is preparing to submit the Factor XIIa inhibitor for US FDA approval for monthly prophylaxis of hereditary angioedema and expand the firm’s HAE franchise.
Takeda Moves Takhzyro Toward Dominant Position In Pediatric HAE
The company announced data from the Phase III SPRING study of Takhzyro in children aged 2-11; there is no approved long-term prophylactic therapy for children under 6.
BioCryst & Celgene Suffer English Funding Setback For Rare Disease Drugs
Orladeyo and Inrebic have been approved in Great Britain but they will not be available under the National Health Service unless their manufacturers can convince the health technology assessment body, NICE, that their products are cost-effective.